Review decision – June 2018
Decision to partially review and partially appraise the topic
The Institute was proposing a part-review and part re-issue of the guidance should be planned into the appraisal work programme. For those people within the marketing authorisation with phakic lenses, for whom fluocinolone is not recommended in TA301. The part-review will be conducted through the STA process.
For those people with pseudophakic lenses where fluocinolone is already recommended in TA301, a re-issue of these, unchanged, positive recommendations, accounting for the new PAS is suggested.
After consideration of all of the comments received during the Review Consultation, the Technology Appraisals programme has decided to proceed with this proposal.
Consequently, the guidance will be partially reviewed and partially appraised.
This page was last updated: